# Type 2 Diabetes Pharmacotherapy Reference (trimmed)

*Key drug classes, benefits, and trial citations for clinical decision support. For full detail, use the Knowledge Base retrieval.*

## SGLT-2 Inhibitors

- **Mechanism:** Urinary glucose excretion. A1C: intermediate–high. Weight: loss. Hypoglycemia: low. Renal: initiate if eGFR ≥20; continue for cardiorenal benefit.
- **Benefits:** MACE reduction (canagliflozin, empagliflozin, dapagliflozin); HF hospitalization reduction; CKD progression slowing.
- **Cite:** EMPA-REG OUTCOME, EMPA-KIDNEY (28% CKD progression/CV death reduction), CREDENCE, DAPA-HF, DAPA-CKD. Empagliflozin (Jardiance), Canagliflozin (Invokana), Dapagliflozin (Farxiga) have CV/HF/CKD benefit; Ertugliflozin (Steglatro) HF only; Bexagliflozin (Brenzavy) no outcome data.

## GLP-1 Receptor Agonists

- **Mechanism:** Incretin mimetic. A1C: high–very high. Weight: loss. Hypoglycemia: low. Renal: no dose adjustment for dulaglutide, semaglutide, liraglutide.
- **Benefits:** MACE reduction (dulaglutide, liraglutide, semaglutide); albuminuria reduction; weight loss; MASH (semaglutide).
- **Cite:** SUSTAIN-6 (MACE), FLOW (24% kidney disease progression/CV death in T2D with CKD), LEADER, REWIND. Semaglutide injectable (Ozempic): CV, HF, CKD benefit. Dulaglutide (Trulicity): CV. Do not combine with DPP-4.

## Dual GIP/GLP-1 (Tirzepatide)

- **Benefits:** Superior A1C and weight loss vs GLP-1 RAs; HF benefit in HFpEF with obesity.
- **Cite:** SURPASS-2 (vs semaglutide), SUMMIT (CV death/worsening HF in HFpEF).

## DPP-IV Inhibitors

- **Mechanism:** Increases endogenous incretin. A1C: intermediate. Weight: neutral. Hypoglycemia: low.
- **Cautions:** No CV or renal benefit; potential HF risk (saxagliptin); do not combine with GLP-1 RAs. Cite TECOS (CV safety, no benefit).

## Biguanides (Metformin)

- **First-line.** A1C: high. Weight: neutral. Hypoglycemia: low. Renal: contraindicated eGFR <30; reduce dose eGFR 30–45.
- **Cite:** UKPDS (CV mortality benefit). KDIGO: first line for CKD prevention.

## Sulfonylurea (SUR-1)

- **High hypoglycemia risk.** Generally stop when basal insulin started; must stop when bolus insulin started. Use cautiously in CKD (avoid glyburide; glipizide/glimepiride with caution). Cite CAROLINA (CV safety).

## TZDs (Pioglitazone)

- **Cautions:** HF risk (contraindicated in HF); fluid retention; fracture risk. Cite PROactive.

## Basal / Bolus Insulin

- **High hypoglycemia risk;** dose reduce as eGFR declines. Cite DEVOTE (basal, severe hypoglycemia reduction).

## Clinical decision framework (ADA 2026)

| Scenario | First-line |
|----------|------------|
| Established ASCVD | GLP-1 RA with CV benefit OR SGLT2i with CV benefit |
| High CV risk (age ≥55, ≥2 risk factors) | GLP-1 RA OR SGLT2i |
| Heart Failure (HFrEF/HFpEF) | SGLT2i; add tirzepatide/semaglutide for HFpEF + obesity |
| CKD (eGFR 20–60 or albuminuria) | SGLT2i OR GLP-1 RA (semaglutide preferred) |
| Weight priority | Tirzepatide or Semaglutide; dulaglutide, liraglutide also effective |
| MASLD/MASH | Semaglutide (FDA approved), Pioglitazone, or Tirzepatide |

*Use Knowledge Base retrieval for full tables, dosing, and detailed trial citations.*
